GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » 5-Year RORE %

Augmedix (Augmedix) 5-Year RORE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Augmedix 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Augmedix does not have enough data to calculate 5-Year RORE %.


Augmedix 5-Year RORE % Historical Data

The historical data trend for Augmedix's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix 5-Year RORE % Chart

Augmedix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
- - - - -

Augmedix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Augmedix's 5-Year RORE %

For the Health Information Services subindustry, Augmedix's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Augmedix's 5-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Augmedix's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Augmedix's 5-Year RORE % falls into.



Augmedix 5-Year RORE % Calculation

Augmedix's 5-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 5-year before.


Augmedix  (NAS:AUGX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Augmedix 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Augmedix's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Augmedix (Augmedix) Business Description

Traded in Other Exchanges
N/A
Address
111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
Executives
Paul Ginocchio officer: Chief Financial Officer C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor director 5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner director C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly director C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc director, 10 percent owner ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo director 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins officer: Chief Revenue Officer C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber officer: CHIEF OPERATING OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil officer: CHIEF STRATEGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris director, officer: PRESIDENT, CEO, AND SECRETARY C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee officer: CHIEF TECHNOLOGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw director 4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian director, 10 percent owner C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103